Site icon Phillips Ormonde Fitzpatrick | Patents, Trade Marks & IP Law

Phillips Ormonde Fitzpatrick promotes two new Principals

We are excited to announce that Marine Guillou and Danielle Burns have been promoted to Principals of the firm, effective 1 July 2021.

“These two promotions reflect our confidence in the future of Phillips Ormonde Fitzpatrick coming out of the COVID-19 pandemic, and continue our development of client-focused talent within the firm”, said Ross McFarlane, Managing Principal.

“Marine and Dani are both dynamic professionals, and they are a testament to our strong and diverse pipeline of future leaders. We value their outstanding practice management, cross-firm teamwork and professional excellence. I look forward to their contribution to the ongoing success of our firm”, he said.

Marine Guillou  specialises in anti-counterfeiting programs, customs proceedings and training, and advising clients on trade mark prosecution. Marine has built the largest anti-counterfeiting practice in Australia. 

Prior to moving to Australia and joining POF, Marine was notably in-house lawyer for the French anti-counterfeiting Group, Union Des Fabricants (Unifab), and worked as an anti-counterfeiting area Manager with Société Bic. Marine has participated in working groups such as Interpol Intellectual Property Crime Action Group and Global Anti-Counterfeiting Group.

Danielle Burns has extensive experience as a scientist and as a patent attorney with expertise in patent strategy, protection and enforcement in the Biotech sector.  She has a strong understanding of global patent and regulatory exclusivities (including data and market exclusivities) and has facilitated entry of several biopharmaceuticals (including antibodies and antisense molecules), diagnostics, cellular therapeutics, and agricultural products (including transgenic plants) to market.

Danielle has a diverse client base – working with several local and overseas biotech companies, including small to medium entities, big pharmaceutical and generics/biosimilar companies as well as academic institutions to strategically protect their intellectual property and facilitate market entry.

Exit mobile version